Log in to search using one of your social media accounts:


Disarm Therapeutics Appoints Peter Keller Chief Business Officer

CAMBRIDGE, Mass., Dec. 19, 2017 -- (Healthcare Sales &Marketing Network) -- Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological diseas... Biopharmaceuticals, Neurology, Personnel Disarm Therapeutics, SARM1, multiple sclerosis, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

More News: ALS | Biotechnology | Brain | Marketing | Multiple Sclerosis | Neurology | Pharmaceuticals